Nagapetir represents a novel therapeutic method targeting activated protein C, a crucial element in the coagulation sequence. This molecule functions as a specific factor blocker, demonstrating potential in diminishing clot-related events. Preclinical research have shown favorable outcomes, suggesting that Nagapetir may offer a different option for